Early proof-of-concept
Preclinical proof-of-concept data with a clear development plan toward clinical testing.
Investments
Early-stage venture capital for autoimmune innovation.
IBC invests in early-stage companies developing autoimmune therapeutics, diagnostics and enabling technology - backing the founders who turn breakthrough science into life-changing treatments.
Our Investment Approach
Catalytic capital, deployed where the science needs it most.
Early-stage autoimmune companies need risk-tolerant capital to reach their first value-inflection points - a resource that is increasingly scarce. IBC invests alongside founders to generate decisive data, unlock follow-on financing and advance therapies and diagnostics toward commercial development.
- Hands-on company building through the IBC Venture Studio
- Pre-clinical to IND-enabling stage
- Diagnostics at analytical or clinical validation
- Therapeutics, diagnostics and enabling tech
- Syndication-friendly with VCs and strategics
- Clear milestones to Seed or Series A readiness
IBC Venture Studio
Beyond capital, we build companies.
Through the IBC Venture Studio, our team works hand-in-hand with founders and academic spinouts to shape strategy, operations and go-to-market, helping translate promising science into durable ventures. By pairing venture discipline with a patient-first mission, IBC aims to accelerate the path from promising science to meaningful patient outcomes.
Investment Criteria
What we look for in early-stage companies.
Validated signal
Preliminary data supporting both therapeutic potential and commercial viability in the target indication.
Milestone-driven tranches
Capital deployed in tranches tied to measurable de-risking events that position companies for follow-on financing.
How We Invest
Right-sized capital, syndication-friendly.
Exploratory seed
Hypothesis validation
Earliest catalytic capital to validate hypotheses and generate decisive data.
Initial investment
Lead or co-invest
Flexibility to syndicate alongside aligned VCs and strategics.
Selective follow-on
Catalytic top-ups
Reserved capital to bridge portfolio companies to a traditional Seed or Series A round.
Evergreen Model
Every return is reinvested in the mission.
- 100% of returns recycled into new early-stage investments.
- No carry, no management fee - every dollar is reinvested in the next generation of autoimmune companies.
- Aligned with founders, patients and co-investors.
Founder Inquiries
Building a company that moves autoimmune care forward?
We welcome pitches from early-stage startups and academic spinouts. Share your team, the science and the milestones you're raising toward - we'll get back to you.
